viewMaxCyte Inc

Major announcements for MaxCyte

MaxCyte Inc (LON:MXCT) has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Gilead Sciences Inc (NASDAQ:GILD), to use its Flow Electroporation Technology (FET) platform. The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering. News here too on MaxCyte's expanded relationship with CRISPR Therapeutics as part of its quest to develop new gene therapies for the treatment of cancer after the pair signed a commercial licence agreement.
Doug Doerfler, MaxCyte Chief Executive, said the agreement was a “validation” of his firm’s technology, while CRISPR boss, Samarth Kulkarni, said he was pleased to have secured access to “the leading ex vivo delivery platform for both clinical and commercial use”.

Quick facts: MaxCyte Inc

Price: 173.5 GBX

Market: AIM
Market Cap: £132.87 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...



MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read